Therefore, it is crucial to achieve optimal binding affinity in NKG2D-CARs, allowing the CARs to effectively engage their targets and execute T cell effector functions, while simultaneously minimizing on-target but off-tumor effects, especially when targeting ligands that are expressed at low levels on healthy cells. The gene discussed is KLRK1; the disease is neoplasm.